Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) EBIT (2019 - 2025)

Historic EBIT for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to -$92.5 million.

  • Kymera Therapeutics' EBIT fell 2828.05% to -$92.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$332.3 million, marking a year-over-year decrease of 6597.02%. This contributed to the annual value of -$261.6 million for FY2024, which is 5805.9% down from last year.
  • Per Kymera Therapeutics' latest filing, its EBIT stood at -$92.5 million for Q3 2025, which was down 2828.05% from -$84.6 million recorded in Q2 2025.
  • Kymera Therapeutics' EBIT's 5-year high stood at -$13.2 million during Q1 2021, with a 5-year trough of -$92.5 million in Q3 2025.
  • Its 5-year average for EBIT is -$49.5 million, with a median of -$44.9 million in 2022.
  • As far as peak fluctuations go, Kymera Therapeutics' EBIT soared by 5000.78% in 2023, and later crashed by 31815.97% in 2024.
  • Quarter analysis of 5 years shows Kymera Therapeutics' EBIT stood at -$34.0 million in 2021, then decreased by 13.64% to -$38.6 million in 2022, then surged by 50.01% to -$19.3 million in 2023, then tumbled by 318.16% to -$80.8 million in 2024, then dropped by 14.57% to -$92.5 million in 2025.
  • Its last three reported values are -$92.5 million in Q3 2025, -$84.6 million for Q2 2025, and -$74.4 million during Q1 2025.